GETI-B Stock Analysis: Getinge ser. | ST
Medical Devices | ST, Sweden | Market Cap: 55.128m SEK | 12M Return: 10.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 92.0M
EPS Trend: 31.5%
Qual. Beats: 0
Rev. Trend: 87.2%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Getinge AB (publ) is a Swedish medical technology company founded in 1904 and headquartered in Gothenburg, operating across three reporting segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its product portfolio spans operating room equipment, anesthesia, intensive-care infrastructure, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), intra-aortic balloon counterpulsation, surgical perfusion, and endoscopic vessel harvesting, along with sterilization, cleaning, disinfection, and sterile supply management solutions for hospitals. The Life Science segment extends these capabilities into pharmaceutical and bioprocessing applications, including terminal sterilization, aseptic transfer, bioreactor preparation, and vivarium solutions. The company distributes through direct sales subsidiaries, agents, and distributors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
As a mid-cap constituent in the Health Care Equipment sub-industry, Getinge operates a diversified business model that combines capital medical devices, consumables, and recurring service revenue across acute hospital care and pharmaceutical production. Its dual exposure to clinical care and life sciences provides some diversification between cyclical hospital capital spending and the more regulated, longer-cycle bioprocessing market.
- Life Science segment accelerates on biopharma capex recovery
- Hospital budget tightening weighs on Surgical Workflows orders
- Acute Care Therapies margins face post-COVID ventilator normalization
| Net Income: 2.36b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.59 > 1.0 |
| NWC/Revenue: 13.23% < 20% (prev 12.02%; Δ 1.21% < -1%) |
| CFO/TA 0.08 > 3% & CFO 4.58b > Net Income 2.36b |
| Net Debt (8.48b) to EBITDA (6.01b): 1.41 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (272.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 45.70% > 18% (prev 46.00%; Δ -0.31% > 0.5%) |
| Asset Turnover: 57.65% > 50% (prev 59.01%; Δ -1.37% > 0%) |
| Interest Coverage Ratio: 6.49 > 6 (EBIT TTM 3.96b / Interest Expense TTM 609.0m) |
| A: 0.08 (Total Current Assets 17.4b - Total Current Liabilities 12.9b) / Total Assets 58.0b |
| B: 0.38 (Retained Earnings 22.0b / Total Assets 58.0b) |
| C: 0.07 (EBIT TTM 3.96b / Avg Total Assets 59.1b) |
| D: 1.15 (Book Value of Equity 31.0b / Total Liabilities 27.0b) |
| Altman-Z'' = 3.40 = A |
| DSRI: 0.98 (Receivables 6.84b/7.31b, Revenue 34.1b/35.6b) |
| GMI: 1.01 (GM 46.00% / 45.70%) |
| AQI: 1.00 (AQ_t 0.61 / AQ_t-1 0.61) |
| SGI: 0.96 (Revenue 34.1b / 35.6b) |
| TATA: -0.04 (NI 2.36b - CFO 4.58b) / TA 58.0b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at SEK 207.70 with a total of 544,570 shares traded. Over the past week, the price has changed by -0.14%, over one month by +8.69%, over three months by +10.86% and over the past year by +10.26%.
Current recommended Stop Loss: 202.40 (which is 2.6% or 1.3 ATR below the current price).
Getinge ser. has no consensus analysts rating.
P/E Trailing = 23.3988
P/E Forward = 17.6056
P/S = 1.617
P/B = 1.829
P/EG = 1.646
Revenue TTM = 34.1b SEK
EBIT TTM = 3.96b SEK
EBITDA TTM = 6.01b SEK
Long Term Debt = 7.95b SEK (from longTermDebt, last quarter)
Short Term Debt = 1.99b SEK (from shortTermDebt, last quarter)
Debt = 12.5b SEK (from shortLongTermDebtTotal, last quarter) + Leases 1.51b
Net Debt = 8.48b SEK (calculated: Debt 12.5b - CCE 4.02b)
Enterprise Value = 63.6b SEK (55.1b + Debt 12.5b - CCE 4.02b)
Interest Coverage Ratio = 6.49 (Ebit TTM 3.96b / Interest Expense TTM 609.0m)
EV/FCF = 19.19x (Enterprise Value 63.6b / FCF TTM 3.31b)
FCF Yield = 5.21% (FCF TTM 3.31b / Enterprise Value 63.6b)
FCF Margin = 9.72% (FCF TTM 3.31b / Revenue TTM 34.1b)
Net Margin = 6.92% (Net Income TTM 2.36b / Revenue TTM 34.1b)
Gross Margin = 45.70% ((Revenue TTM 34.1b - Cost of Revenue TTM 18.5b) / Revenue TTM)
Gross Margin QoQ = 48.45% (prev 44.15%)
Tobins Q-Ratio = 1.10 (Enterprise Value 63.6b / Total Assets 58.0b)
Interest Expense / Debt = 4.87% (Interest Expense 609.0m / Debt 12.5b)
Taxrate = 27.84% (916.0m / 3.29b)
NOPAT = 2.85b (EBIT 3.96b * (1 - 27.84%))
Current Ratio = 1.35 (Total Current Assets 17.4b / Total Current Liabilities 12.9b)
Debt / Equity = 0.40 (Debt 12.5b / totalStockholderEquity, last quarter 31.0b)
Debt / EBITDA = 1.41 (Net Debt 8.48b / EBITDA 6.01b)
Debt / FCF = 2.56 (Net Debt 8.48b / FCF TTM 3.31b)
Total Stockholder Equity = 29.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.99% (Net Income 2.36b / Total Assets 58.0b)
RoE = 7.97% (Net Income TTM 2.36b / Total Stockholder Equity 29.6b)
RoCE = 10.53% (EBIT 3.96b / Capital Employed (Equity 29.6b + L.T.Debt 7.95b))
RoIC = 6.29% (NOPAT 2.85b / Invested Capital 45.4b)
WACC = 6.58% (E(55.1b)/V(67.6b) * Re(7.28%) + D(12.5b)/V(67.6b) * Rd(4.87%) * (1-Tc(0.28)))
Discount Rate = 7.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 56.65 | Cagr: 0.00%
[DCF] Terminal Value 77.97% ; FCFF base≈2.98b ; Y1≈3.42b ; Y5≈5.03b
[DCF] Fair Price = 264.6 (EV 75.7b - Net Debt 8.48b = Equity 67.2b / Shares 254.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 31.46 | EPS CAGR: 2.49% | SUE: -0.11 | # QB: 0
Revenue Correlation: 87.17 | Revenue CAGR: 6.20% | SUE: -0.97 | # QB: -2
EPS current Quarter (2026-06-30): EPS=2.36 | Chg30d=+0.28% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=2.55 | Chg30d=-1.93% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=11.67 | Chg30d=-0.21% | Revisions=-25% | GrowthEPS=+3.4% | GrowthRev=+0.1%
EPS next Year (2027-12-31): EPS=13.28 | Chg30d=+0.04% | Revisions=-25% | GrowthEPS=+13.8% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -44% (up=1, down=5)